| Authors: |
Ho VT; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Kim HT; Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA., Brock J; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Galinsky I; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Daley H; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Reynolds C; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Weber A; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Pozdnyakova O; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Severgnini M; Center for Immuno-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Nikiforow S; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Cutler C; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Koreth J; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Alyea EP; Department of Hematology/Oncology, Duke Cancer Institute, Durham, NC., Antin JH; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Gooptu M; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Romee R; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Shapiro R; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Chen YB; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA., Rosenblatt J; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and., Avigan D; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and., Hodi FS; Center for Immuno-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Dranoff G; Novartis Institutes for BioMedical Research, Boston, MA., Wu CJ; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Ritz J; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Soiffer RJ; Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. |
